IMTX Immatics N.V. Net earnings per share growth this year

AI-platform automation of drug synthesis optimizes Immatics N.V. (IMTX) capacities, impacting year-over-year EPS growth rates, where the value is maintained at -19.10. The development of ACTengine and strategic alliances strengthen the financial foundation, while overall T-cell therapy sector dynamics and strict regulatory oversight determine the scaling pace of this ecosystem.

Immatics (IMTX): Net earnings per share growth this year from 07/04/2022 to 11/14/2026

Analytical breakdowns and data insights for company Immatics Biotechnologies (IMTX)

- current quotes and average value forecast:

Market Chart Immatics Biotechnologies|IMTX - Price Target Chart

- market capitalization data:

Market Valuation Immatics N.V.|IMTX - Total Company Value

- company book value details:

Accounting Value per Share Immatics|IMTX - Company Net Assets|Market Capitalization to Book Value Ratio immatics.com|IMTX - Aggregate Company Assets

- debt and liquidity details:

- net income and valuation ratios data:

IMTX - Net Profit|Expected Net Profit Immatics N.V.|IMTX - Price to Earnings Ratio|Future Price to Earnings Multiple Immatics N.V.|IMTX - PEG Multiple|EV/EBITDA Multiple Immatics N.V.|IMTX - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Immatics|IMTX - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months immatics.com|IMTX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Immatics N.V.

- company sales and revenue statistics:

IMTX - Company Revenue|Company Future Sales Volume Immatics Biotechnologies|IMTX - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple Immatics

Summary company analysis:IMTX (Immatics N.V.)

Investors assess an asset's margin of safety through EPS dynamics, where a positive trend confirms the effectiveness of earnings per share capitalization relative to the previous period. The development of the immunotherapy ecosystem at Immatics N.V. (IMTX) directly impacts the year-over-year shift in earnings per share on the GURU.Markets platform, transforming scientific research into a fundamental growth driver for this high-tech biopharmaceutical asset.

Key competitors